Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
Samantha B. Kemp, Noah Cheng, Nune Markosyan, et al.
Cancer Discovery (2022) Vol. 13, Iss. 2, pp. 298-311
Open Access | Times Cited: 220

Showing 1-25 of 220 citing articles:

Pancreatic cancer: Advances and challenges
Christopher J. Halbrook, Costas A. Lyssiotis, Marina Pasca di Magliano, et al.
Cell (2023) Vol. 186, Iss. 8, pp. 1729-1754
Open Access | Times Cited: 529
Therapeutic developments in pancreatic cancer
Zilun Hu, Eileen M. O’Reilly
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 21, Iss. 1, pp. 7-24
Closed Access | Times Cited: 123
KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells
Krishnan K. Mahadevan, Kathleen M. McAndrews, Valerie S. LeBleu, et al.
Cancer Cell (2023) Vol. 41, Iss. 9, pp. 1606-1620.e8
Open Access | Times Cited: 99
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
Shubham Pant, Zev A. Wainberg, Colin D. Weekes, et al.
Nature Medicine (2024) Vol. 30, Iss. 2, pp. 531-542
Open Access | Times Cited: 74
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Jingjing Jiang, Lingyan Jiang, Benjamin J. Maldonato, et al.
Cancer Discovery (2024) Vol. 14, Iss. 6, pp. 994-1017
Open Access | Times Cited: 68
Targeting KRAS in cancer
Anupriya Singhal, Bob T. Li, Eileen M. O’Reilly
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 969-983
Closed Access | Times Cited: 67
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
Urszula N. Wasko, Jingjing Jiang, Tanner C. Dalton, et al.
Nature (2024) Vol. 629, Iss. 8013, pp. 927-936
Open Access | Times Cited: 55
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Míriam Molina‐Arcas, Julian Downward
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 338-357
Open Access | Times Cited: 46
Next batter up! Targeting cancers with KRAS-G12D mutations
Mara N. Zeissig, Lauren M. Ashwood, Olga Kondrashova, et al.
Trends in cancer (2023) Vol. 9, Iss. 11, pp. 955-967
Open Access | Times Cited: 43
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
Abdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 38
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Julien Dilly, Megan T. Hoffman, Laleh Abbassi, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2135-2161
Closed Access | Times Cited: 36
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer
Xinyuan Tong, Ayushi Patel, Eejung Kim, et al.
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 413-428.e7
Open Access | Times Cited: 32
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers
Jeffrey A. Klomp, Jennifer E. Klomp, Clint A. Stalnecker, et al.
Science (2024) Vol. 384, Iss. 6700
Open Access | Times Cited: 30
Combinatorial strategies to target RAS-driven cancers
Naiara Perurena, Lisa Situ, Karen Cichowski
Nature reviews. Cancer (2024) Vol. 24, Iss. 5, pp. 316-337
Closed Access | Times Cited: 22
The Role of Oxidative Stress in Tumorigenesis and Progression
Kexin Li, Zhangyuzi Deng, Chunran Lei, et al.
Cells (2024) Vol. 13, Iss. 5, pp. 441-441
Open Access | Times Cited: 18
Targeting KRAS in pancreatic cancer
Sandra Stickler, Barbara H. Rath, Gerhard Hamilton
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2024) Vol. 32, Iss. 5, pp. 799-805
Open Access | Times Cited: 18
KRAS G12C inhibitor combination therapies: current evidence and challenge
Hirotaka Miyashita, Shumei Kato, David S. Hong
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 15
AGER-dependent macropinocytosis drives resistance to KRAS-G12D–targeted therapy in advanced pancreatic cancer
Changfeng Li, Yuanda Liu, Chang Liu, et al.
Science Translational Medicine (2025) Vol. 17, Iss. 783
Closed Access | Times Cited: 2
Dual Inhibition of KRASG12D and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma
Kevin Christian Montecillo Gulay, Xinlian Zhang, Vasiliki Pantazopoulou, et al.
Cancer Research (2023) Vol. 83, Iss. 18, pp. 3001-3012
Open Access | Times Cited: 36
A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer
Daoyan Wei, Liang Wang, Xiangsheng Zuo, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 4, pp. 655-662
Open Access | Times Cited: 35
Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas
Marina Salmón, Ruth Álvarez, Coral Fustero‐Torre, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 7
Open Access | Times Cited: 32
Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8+ T cells
Krishnan K. Mahadevan, Valerie S. LeBleu, Elena V. Ramirez, et al.
Developmental Cell (2023) Vol. 58, Iss. 17, pp. 1562-1577.e8
Open Access | Times Cited: 31
A prime editor mouse to model a broad spectrum of somatic mutations in vivo
Zackery A. Ely, Nicolas Mathey‐Andrews, Santiago Naranjo, et al.
Nature Biotechnology (2023)
Open Access | Times Cited: 29
Opportunities for Achieving the Cancer Moonshot Goal of a 50% Reduction in Cancer Mortality by 2047
Meredith S. Shiels, Stanley Lipkowitz, Nicole G. Campos, et al.
Cancer Discovery (2023) Vol. 13, Iss. 5, pp. 1084-1099
Open Access | Times Cited: 28
KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
Zining Zhang, Heng Zhang, Xiang Liao, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 27
Page 1 - Next Page

Scroll to top